Safety and Feasibility of Immuno-OCT
Conditions: Colon Carcinoma; Barrett Esophagus; Gastrointestinal Dysplasia Intervention: Drug: Bevacizumab-800CW Sponsor: University Medical Center Groningen Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials